Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial

Hilda Angela Mujuru, Ellen White, Adeodata R Kekitiinwa, Abbas Lugemwa, Cissy Kityo, Avy Violari, Grace Miriam Ahimbisibwe, Ebrahim Variava, Moherndran Archary, Mark Cotton, Pradthana Ounchanum, Thanyawee Puthanakit, Suparat Kanjanavanit, Chaiwat Ngampiyaskul, Robin Kobbe, Srini Bandi, Cristina Epalza, Mutsawashe Bwakura-Dangarembizi, Dickson Bbuye, Mariam Kasozi, Elizabeth Kaudha, Tim R Cressey, Carlo Giaquinto, Lungile Jafta, Alasdair Bamford, Pablo Rojo, Diana M Gibb, Anna Turkova, Deborah Ford

Open source

DOI: 10.1093/ofid/ofag266
Published: 2026-04-28
Container: Open Forum Infectious Diseases
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ofid/ofag266,
  title = {Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial},
  author = {Hilda Angela Mujuru and Ellen White and Adeodata R Kekitiinwa and Abbas Lugemwa and Cissy Kityo and Avy Violari and Grace Miriam Ahimbisibwe and Ebrahim Variava and Moherndran Archary and Mark Cotton and Pradthana Ounchanum and Thanyawee Puthanakit and Suparat Kanjanavanit and Chaiwat Ngampiyaskul and Robin Kobbe and Srini Bandi and Cristina Epalza and Mutsawashe Bwakura-Dangarembizi and Dickson Bbuye and Mariam Kasozi and Elizabeth Kaudha and Tim R Cressey and Carlo Giaquinto and Lungile Jafta and Alasdair Bamford and Pablo Rojo and Diana M Gibb and Anna Turkova and Deborah Ford},
  year = {2026},
  journal = {Open Forum Infectious Diseases},
  doi = {10.1093/ofid/ofag266},
  url = {https://doi.org/10.1093/ofid/ofag266}
}

RIS

TY  - JOUR
TI  - Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial
AU  - Hilda Angela Mujuru
AU  - Ellen White
AU  - Adeodata R Kekitiinwa
AU  - Abbas Lugemwa
AU  - Cissy Kityo
AU  - Avy Violari
AU  - Grace Miriam Ahimbisibwe
AU  - Ebrahim Variava
AU  - Moherndran Archary
AU  - Mark Cotton
AU  - Pradthana Ounchanum
AU  - Thanyawee Puthanakit
AU  - Suparat Kanjanavanit
AU  - Chaiwat Ngampiyaskul
AU  - Robin Kobbe
AU  - Srini Bandi
AU  - Cristina Epalza
AU  - Mutsawashe Bwakura-Dangarembizi
AU  - Dickson Bbuye
AU  - Mariam Kasozi
AU  - Elizabeth Kaudha
AU  - Tim R Cressey
AU  - Carlo Giaquinto
AU  - Lungile Jafta
AU  - Alasdair Bamford
AU  - Pablo Rojo
AU  - Diana M Gibb
AU  - Anna Turkova
AU  - Deborah Ford
PY  - 2026
JO  - Open Forum Infectious Diseases
DO  - 10.1093/ofid/ofag266
UR  - https://doi.org/10.1093/ofid/ofag266
ER  -

APA

Mujuru, H. A., White, E., Kekitiinwa, A. R., Lugemwa, A., Kityo, C., Violari, A., Ahimbisibwe, G. M., Variava, E., Archary, M., Cotton, M., Ounchanum, P., Puthanakit, T., Kanjanavanit, S., Ngampiyaskul, C., Kobbe, R., Bandi, S., Epalza, C., Bwakura-Dangarembizi, M., Bbuye, D., Kasozi, M., Kaudha, E., Cressey, T. R., Giaquinto, C., Jafta, L., Bamford, A., Rojo, P., Gibb, D. M., Turkova, A., & Ford, D. (2026). Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofag266

Source records

crossref · retrieved 2026-09-25T15:41:20.170Z